Zobrazeno 1 - 10
of 1 522
pro vyhledávání: '"hypomethylating agent"'
Autor:
Maria Fortunata Lofiego, Francesca Piazzini, Francesca Pia Caruso, Francesco Marzani, Laura Solmonese, Emma Bello, Fabrizio Celesti, Maria Claudia Costa, Teresa Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Sandra Coral, Anna Maria Di Giacomo, Michele Maio, Alessia Covre, The EPigenetic Immune-oncology Consortium Airc (EPICA) investigators
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor, that is refractory to standard treatment and to immunotherapy with immune-checkpoint inhibitors (ICI). Noteworthy, melanoma brain metastases (MM-BM), that s
Externí odkaz:
https://doaj.org/article/de9304cb7f1e45d7b01e1059c5afd11b
Autor:
Shuya Feng, Yigang Yuan, Zihan Lin, Min Li, Daijiao Ye, Liuzhi Shi, Danyang Li, Min Zhao, Chen Meng, Xiaofei He, Shanshan Wu, Fang Xiong, Siyu Ye, Junjun Yang, Haifeng Zhuang, Lili Hong, Shenmeng Gao
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2024)
Abstract Background Ferroptosis is a new form of nonapoptotic and iron-dependent type of cell death. Glutathione peroxidase-4 (GPX4) plays an essential role in anti-ferroptosis by reducing lipid peroxidation. Although acute myeloid leukemia (AML) cel
Externí odkaz:
https://doaj.org/article/84b5eef75bfa4328af9bf045a1b26690
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiaoning Wang, Jiashuo Guo, Yan Liu, Na Zheng, Shaohan Xu, Lianhui Wu, Ruirui Yuan, Liying Xue, Jie Li
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematological malignancy with a highly aggressive behavior and median survival of
Externí odkaz:
https://doaj.org/article/be087bedc3194c63bc7040d33a80f6fd
Autor:
Hui Liu, Hao Jiang, Hongyan Tong, Ruixiang Xia, Linhua Yang, Hongguo Zhao, Jian Ouyang, Hai Bai, Hui Sun, Li Hou, Ming Jiang, Yun Zeng, Zhuogang Liu, Aibin Liang, Yinghua Xie, Kang Yu, Zhimin Zhai, Li Liu, Jinsong Jia, Rong Fu, Zonghong Shao
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 13885-13893 (2023)
Abstract Background The hypomethylating agent decitabine is the standard therapy for intermediate or high risk myelodysplastic syndrome (MDS). Methods In this trial, 191 adult patients with intermediate/high risk MDS (IPSS score ≥ 0.5) randomly rec
Externí odkaz:
https://doaj.org/article/50a8af396c0a41e28fc1444429af2f12
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6177-6196 (2023)
Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition
Externí odkaz:
https://doaj.org/article/1b715c1349b94bfd90324ecd0f55f5af
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 269-272 (2023)
Abstract To date, allogenic stem cell transplant (ASCT) remains the only potential curative option for patients with primary myelofibrosis (PMF). However, relapse rates and associated mortality remain a concern. A second ASCT may not be feasible due
Externí odkaz:
https://doaj.org/article/48dac9ddf0794a52b5d7b765694ea41b
Autor:
Moreno Vanegas Y, Badar T
Publikováno v:
Cancer Management and Research, Vol Volume 14, Pp 3527-3538 (2022)
Yenny Moreno Vanegas, Talha Badar Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USACorrespondence: Talha Badar, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32
Externí odkaz:
https://doaj.org/article/20fd728430fa47e28b62a003702b1f56
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-21 (2022)
Abstract Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increasingly aggressive
Externí odkaz:
https://doaj.org/article/fcec544caaf545a083374c2d3949e490